Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.
Department of Structural Biology, Weizmann Institute of Science, Rehovot 76100, Israel.
Int J Mol Sci. 2020 May 5;21(9):3270. doi: 10.3390/ijms21093270.
The two major proteins involved in Alzheimer's disease (AD) are the amyloid precursor protein (APP) and Tau. Here, we demonstrate that these two proteins can bind to each other. Four possible peptides APP1 (390-412), APP2 (713-730), Tau1 (19-34) and Tau2 (331-348), were predicted to be involved in this interaction, with actual binding confirmed for APP1 and Tau1. In vivo studies were performed in an Alzheimer Disease animal model-APP double transgenic (Tg) 5xFAD-as well as in 5xFAD crossed with Tau transgenic 5xFADXTau (FT), which exhibit declined cognitive reduction at four months of age. Nasal administration of APP1 and Tau1 mixture, three times a week for four or five months, reduced amyloid plaque burden as well as the level of soluble Aβ 1-42 in the brain. The treatment prevented the deterioration of cognitive functions when initiated at the age of three months, before cognitive deficiency was evident, and also at the age of six months, when such deficiencies are already observed, leading to a full regain of cognitive function.
两种主要与阿尔茨海默病(AD)相关的蛋白是淀粉样前体蛋白(APP)和 Tau。在这里,我们证明这两种蛋白可以相互结合。有四个可能的肽 APP1(390-412)、APP2(713-730)、Tau1(19-34)和 Tau2(331-348)被预测参与这种相互作用,实际结合被证实 APP1 和 Tau1。在阿尔茨海默病动物模型——APP 双转基因(Tg)5xFAD 中进行了体内研究,以及在与 Tau 转基因 5xFADXTau(FT)杂交的 APP 双转基因动物中进行了体内研究,这些动物在四个月大时表现出认知能力下降。每周三次鼻腔给予 APP1 和 Tau1 混合物,持续四个月或五个月,可减少脑内淀粉样斑块负担以及可溶性 Aβ 1-42 的水平。该治疗可预防认知功能恶化,当在三个月大时开始治疗,在认知缺陷明显之前开始治疗,或者在六个月大时开始治疗,当已经观察到这种缺陷时开始治疗,从而完全恢复认知功能。